Page last updated: 2024-12-06

pipoxolan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pipoxolan: synonyms BR-18 & rowapraxin refer to HCl; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID28932
CHEMBL ID2110645
CHEBI ID135483
SCHEMBL ID669035
MeSH IDM0040125

Synonyms (35)

Synonym
rowapraxin (tn)
CHEBI:135483
pipoxolan
23744-24-3
D07369
pipoxolan (inn)
5,5-diphenyl-2-(2-piperidin-1-ylethyl)-1,3-dioxolan-4-one
unii-493gzj5t6i
pipossolano [dcit]
pipoxolanum [inn-latin]
493gzj5t6i ,
pipoxolanum
1,3-dioxolan-4-one, 5,5-diphenyl-2-(2-(1-piperidinyl)ethyl)-
pipossolano
pipoxolan [inn:ban]
5,5-diphenyl-2-[2-(1-piperidyl)ethyl]-1,3-dioxolan-4-one hydrochloride
5,5-diphenyl-2-(2-piperidinoethyl)-1,3-dioxolan-4-one
5,5-diphenyl-2-(2'-piperidinoethyl)-1,3-dioxolan-4-one
(+/-)-5,5-diphenyl-2-(2-piperidinoethyl)-1,3-dioxolan-4-one
27769-60-4
1,3-dioxolan-4-one, 5,5-diphenyl-2-(2-piperidinoethyl)-
pipoxolan [who-dd]
pipoxolan [mart.]
5,5-diphenyl-2-(2-(1-piperidinyl)ethyl)-1,3-dioxolan-4-one
pipoxolan [inn]
SCHEMBL669035
CHEMBL2110645
5,5-diphenyl-2-[2-(1-piperidinyl)ethyl]-1,3-dioxolan-4-one #
DXSUDONPFZKWOO-UHFFFAOYSA-N
BCP20276
br 18 pound>>br18 pound>>br-18
Q27259212
A848113
5,5-diphenyl-2-[2-(piperidin-1-yl)ethyl]-1,3-dioxolan-4-one
DTXSID20865113

Research Excerpts

Effects

Pipoxolan (PIPO) has anti-spasmodic effects, and it is used clinically to relieve smooth muscle spasms. Pipoxolan has been reported to have antitumor activity.

ExcerptReferenceRelevance
"Pipoxolan has also been shown to have anticancer activity."( Pipoxolan Exhibits Antitumor Activity Toward Oral Squamous Cell Carcinoma Through Reactive Oxygen Species-mediated Apoptosis.
Chou, PY; Lee, MM; Lin, SY; Sheu, MJ, 2017
)
2.62
"Pipoxolan (PIPO) has anti-spasmodic effects, and it is used clinically to relieve smooth muscle spasms. "( Pipoxolan ameliorates cerebral ischemia via inhibition of neuronal apoptosis and intimal hyperplasia through attenuation of VSMC migration and modulation of matrix metalloproteinase-2/9 and Ras/MEK/ERK signaling pathways.
Chen, YF; Siao, LR; Tsai, HY; Wood, WG; Wu, KJ, 2013
)
3.28
"Pipoxolan has been reported to have antitumor activity. "( Pipoxolan inhibits CL1-5 lung cancer cells migration and invasion through inhibition of MMP-9 and MMP-2.
Chen, YY; Hsu, S; Lee, MM; Liu, PY; Sheu, MJ, 2015
)
3.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.67 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index53.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (14.29%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]